Cystic Fibrosis - Pipeline Review, H2 2015 Is Released Cystic Fibrosis - Pipeline Review, H2 2015 Summary Global Markets Direct s, Cystic Fibrosis - Pipeline Review, H2 2015, provides an overview of the Cystic Fibrosis s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Cystic Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cystic Fibrosis and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-inclass products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Cystic Fibrosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cystic Fibrosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cystic Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cystic Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Cystic Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cystic Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline 1
Browse Complete Report with TOC http://www.idatainsights.com/reports-landingpage.php?id=179097/cystic-fibrosis-pipeline-review-h2-2015 To Get Sample Copy of Report visit http://www.idatainsights.com/reports-landingpage.php?id=179097/cystic-fibrosis-pipeline-review-h2-2015 Table of Contents Table of Contents 2 List of Tables 8 List of Figures 10 Introduction 11 Global Markets Direct Report Coverage 11 Cystic Fibrosis Overview 12 Therapeutics Development 13 Pipeline Products for Cystic Fibrosis - Overview 13 Pipeline Products for Cystic Fibrosis - Comparative Analysis 14 Cystic Fibrosis - Therapeutics under Development by Companies 15 Cystic Fibrosis - Therapeutics under Investigation by Universities/Institutes 21 Cystic Fibrosis - Pipeline Products Glance 22 Late Stage Products 22 Clinical Stage Products 23 Early Stage Products 24 Unknown Stage Products 25 Cystic Fibrosis - Products under Development by Companies 26 Cystic Fibrosis - Products under Investigation by Universities/Institutes 33 Cystic Fibrosis - Companies Involved in Therapeutics Development 34 Actelion Ltd 34
2
Akari Therapeutics, Plc 35 Alaxia SAS 36 AlgiPharma AS 37 AmpliPhi Biosciences Corporation 38 Arcturus Therapeutics, Inc 39 Aridis Pharmaceuticals LLC 40 Bayer AG 41 Boehringer Ingelheim GmbH 42 Carolus Therapeutics, Inc. 43 Celtaxsys, Inc. 44 Chiesi Farmaceutici SpA 45 Cilian AG 46 Concert Pharmaceuticals, Inc. 47 Corbus pharmaceuticals, Inc. 48 Cyclacel Pharmaceuticals, Inc. 49 DiscoveryBiomed, Inc. 50 Errant Gene Therapeutics, LLC 51 Galapagos NV 52 GlaxoSmithKline Plc 53 Grifols, S.A. 54 Grupo Praxis Pharmaceutical SA 55 Horizon Pharma Plc 56 Insmed Incorporated 57 Invion Limited 58 3
JHL Biotech, Inc. 59 Kamada Ltd. 60 La Jolla Pharmaceutical Company 61 Lamellar Biomedical Ltd 62 Laurent Pharmaceuticals Inc. 63 Merck & Co., Inc. 64 Microbion Corporation 65 Mucokinetica Ltd. 66 NanoBio Corporation 67 Nivalis Therapeutics, Inc. 68 Nostrum Pharmaceuticals, LLC 69 Novabiotics Limited 70 Novartis AG 71 OSE Pharma SA 72 Parion Sciences, Inc. 73 Pfizer Inc. 74 Pharmaxis Limited 75 PhaseBio Pharmaceuticals, Inc. 76 Polyphor Ltd. 77 Progenra, Inc. 78 ProQR Therapeutics N.V. 79 Protalix BioTherapeutics, Inc. 80 Proteostasis Therapeutics, Inc. 81 4
PTC Therapeutics, Inc. 82 Pulmatrix, Inc. 83 ReveraGen BioPharma, Inc. 84 Savara Inc. 85 Serendex Pharmaceuticals A/S 86 Shionogi & Co., Ltd. 87 Shire Plc 88 Synovo GmbH 89 TGV-Laboratories 90 The International Biotechnology Center (IBC) Generium 91 Verona Pharma Plc 92 Vertex Pharmaceuticals Incorporated 93 Xenetic Biosciences plc 94 Zambon Company S.p.A. 95 Cystic Fibrosis - Therapeutics Assessment 96 Assessment by Monotherapy Products 96 Assessment by Combination Products 97 Assessment by Target 98 Assessment by Mechanism of Action 102 Assessment by Route of Administration 105 Assessment by Molecule Type 107 Read More http://www.idatainsights.com/reports-landing-page.php?id=179097/cystic-fibrosis-pipelinereview-h2-2015 About Us: 5
iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line. ContactUs: iData Insights Tel: 1-866-237-2965 Web: http://www.idatainsights.com Email: info@idatainsights.com About iData Insights We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.
6